Want to see JP:4587 full AI Analyst Report?
4587 Stock Chart & Stats
¥1669.00
-¥31.00(-1.24%)
At close: 4:00 PM EST
¥1669.00
-¥31.00(-1.24%)
Day’s Range― - ―
52-Week Range¥916.00 - ¥1,818.50
Previous CloseN/A
Volume553.80K
Average Volume (3M)1.01M
Market Cap
¥123.91B
Enterprise Value¥145.51K
Total Cash (Recent Filing)¥25.55B
Total Debt (Recent Filing)¥16.34B
Price to Earnings (P/E)―
Beta0.90
Next Earnings
Aug 12, 2026EPS Estimate
-3.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-27.64
Shares Outstanding130,010,400
10 Day Avg. Volume808,920
30 Day Avg. Volume1,013,253
Financial Highlights & Ratios
PEG Ratio0.46
Price to Book (P/B)4.16
Price to Sales (P/S)11.56
P/FCF Ratio-14.36
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥1,950.00Price Target Upside16.84% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)89.3
Revenue Forecast (FY)¥43.48B
Bulls Say, Bears Say
Bulls Say
Proprietary Discovery PlatformPDPS is a durable competitive asset that underpins PeptiDream’s service offering and differentiation. A proprietary discovery engine supports repeat collaborations, higher switching costs for partners, and scalable discovery work that can generate long-term milestone and royalty streams.
Strong Top-line ReboundA very large revenue rebound indicates accelerating partner engagement and demand for discovery services. Strong top-line growth provides the commercial proof points needed to drive future milestone receipts and royalties and supports longer-term R&D investment if sustained.
Manageable Leverage And Equity BaseModerate leverage and a sizable equity base give the company financial flexibility to absorb near-term cash burn and fund collaborations without excessive refinancing risk. A resilient balance sheet supports multi-quarter R&D cycles and partnership negotiations.
Bears Say
Negative Cash GenerationCash generation has meaningfully reversed to negative in the TTM period, with free cash flow falling sharply versus prior years. Sustained cash burn threatens runway and could force dilutive financing or constrained R&D spending if not remediated through milestones or other funding.
Return To Losses / Weak MarginsThe shift back to negative EBIT/EBITDA and about -20% net margin undermines internal funding capacity and reflects deteriorating unit economics. Negative ROE shows capital currently isn't generating returns, increasing reliance on external funding and partner milestone timing.
Dependence On Partner MilestonesRevenue and cash flow timing are lumpy and tied to partner clinical/regulatory progress and milestone triggers. This structural dependence creates persistent volatility in receipts and planning uncertainty, limiting visibility into sustainable revenue and long-term cash predictability.
Peptidream News
4587 FAQ
What was Peptidream Inc.’s price range in the past 12 months?
Peptidream Inc. lowest stock price was ¥916.00 and its highest was ¥1818.50 in the past 12 months.
What is Peptidream Inc.’s market cap?
Peptidream Inc.’s market cap is ¥123.91B.
When is Peptidream Inc.’s upcoming earnings report date?
Peptidream Inc.’s upcoming earnings report date is Aug 12, 2026 which is in 18 days.
How were Peptidream Inc.’s earnings last quarter?
Peptidream Inc. released its earnings results on May 13, 2026. The company reported -¥6.62 earnings per share for the quarter, beating the consensus estimate of -¥8.05 by ¥1.43.
Is Peptidream Inc. overvalued?
According to Wall Street analysts Peptidream Inc.’s price is currently Undervalued.
Does Peptidream Inc. pay dividends?
Peptidream Inc. does not currently pay dividends.
What is Peptidream Inc.’s EPS estimate?
Peptidream Inc.’s EPS estimate is -3.19.
How many shares outstanding does Peptidream Inc. have?
Peptidream Inc. has 130,010,400 shares outstanding.
What happened to Peptidream Inc.’s price movement after its last earnings report?
Peptidream Inc. reported an EPS of -¥6.62 in its last earnings report, beating expectations of -¥8.05. Following the earnings report the stock price went down -0.178%.
Which hedge fund is a major shareholder of Peptidream Inc.?
Currently, no hedge funds are holding shares in JP:4587
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Peptidream Inc.
PeptiDream Inc. functions as a biopharmaceutical enterprise, concentrating on the identification and progression of therapeutic compounds such as constrained peptides, small molecules, and peptide-drug conjugates. The company's unique product pipeline is underpinned by its proprietary Peptide Discovery Platform System (PDPS), an advanced technology specifically designed for the development of peptide-based drugs. Additionally, PeptiDream maintains an exclusive licensing and collaborative research partnership with Takeda Pharmaceutical Company Limited, aimed at creating peptide drug conjugates for the treatment of neuromuscular conditions. Established in 2006, the company's primary offices are situated in Kawasaki, Japan.
4587 Stock 12 Month Forecast
Average Price Target
¥1,950.00
▲(16.84% Upside)